The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Tumor Immunotherapy Drugs Market Research Report 2024

Global Tumor Immunotherapy Drugs Market Research Report 2024

Publishing Date : Aug, 2023

License Type :
 

Report Code : 1765625

No of Pages : 104

Ask Your Query

Synopsis
Tumor immunotherapy refers to destroying cancer cells by stimulating and activating the patient's own immune system.

Global Tumor Immunotherapy Drugs market is projected to reach US$ 77300 million in 2029, increasing from US$ 42600 million in 2022, with the CAGR of 8.9% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Tumor Immunotherapy Drugs market research.

Key manufacturers engaged in the Tumor Immunotherapy Drugs industry include Bristol Myer Squibb, AstraZeneca, Merck, Roche / Genentech, Ono Pharmaceutical, Regeneron, Innovent, Hengrui Medicine and Junshi Biosciences, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.

When refers to consumption region, % volume of Tumor Immunotherapy Drugs were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Tumor Immunotherapy Drugs market and estimated to attract more attentions from industry insiders and investors.

Report Scope

This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Tumor Immunotherapy Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

By Company

  • Bristol Myer Squibb
  • AstraZeneca
  • Merck
  • Roche / Genentech
  • Ono Pharmaceutical
  • Regeneron
  • Innovent
  • Hengrui Medicine
  • Junshi Biosciences
  • Pfizer, Inc
  • F. Hoffmann-La Roche Ltd
  • Incyte Corporation
  • NewLink Genetics Corporation
  • Celldex Therapeutics, Inc
  • GlaxoSmithKline

Segment by Type

  • Immune Checkpoint Inhibitors
  • Tumor Vaccine
  • Adoptive Immunotherapy
  • Non-specific Immunomodulator

Segment by Application

  • Hospital
  • Clinic
  • Other

Consumption by Region

  • North America (United States, Canada)
  • Europe (Germany, France, U.K., Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia)
  • Latin America (Mexico, Brazil, Argentina)
  • Middle East & Africa (Turkey, Saudi Arabia, UAE)

The Tumor Immunotherapy Drugs report covers below items:

Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source

Index

1 Tumor Immunotherapy Drugs Market Overview
1.1 Product Overview and Scope of Tumor Immunotherapy Drugs
1.2 Tumor Immunotherapy Drugs Segment by Type
1.2.1 Global Tumor Immunotherapy Drugs Market Value Comparison by Type (2023-2029)
1.2.2 Immune Checkpoint Inhibitors
1.2.3 Tumor Vaccine
1.2.4 Adoptive Immunotherapy
1.2.5 Non-specific Immunomodulator
1.3 Tumor Immunotherapy Drugs Segment by Application
1.3.1 Global Tumor Immunotherapy Drugs Market Value by Application: (2023-2029)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Global Tumor Immunotherapy Drugs Market Size Estimates and Forecasts
1.4.1 Global Tumor Immunotherapy Drugs Revenue 2018-2029
1.4.2 Global Tumor Immunotherapy Drugs Sales 2018-2029
1.4.3 Global Tumor Immunotherapy Drugs Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Tumor Immunotherapy Drugs Market Competition by Manufacturers
2.1 Global Tumor Immunotherapy Drugs Sales Market Share by Manufacturers (2018-2023)
2.2 Global Tumor Immunotherapy Drugs Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Tumor Immunotherapy Drugs Average Price by Manufacturers (2018-2023)
2.4 Global Tumor Immunotherapy Drugs Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Tumor Immunotherapy Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Tumor Immunotherapy Drugs, Product Type & Application
2.7 Tumor Immunotherapy Drugs Market Competitive Situation and Trends
2.7.1 Tumor Immunotherapy Drugs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Tumor Immunotherapy Drugs Players Market Share by Revenue
2.7.3 Global Tumor Immunotherapy Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Tumor Immunotherapy Drugs Retrospective Market Scenario by Region
3.1 Global Tumor Immunotherapy Drugs Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Tumor Immunotherapy Drugs Global Tumor Immunotherapy Drugs Sales by Region: 2018-2029
3.2.1 Global Tumor Immunotherapy Drugs Sales by Region: 2018-2023
3.2.2 Global Tumor Immunotherapy Drugs Sales by Region: 2024-2029
3.3 Global Tumor Immunotherapy Drugs Global Tumor Immunotherapy Drugs Revenue by Region: 2018-2029
3.3.1 Global Tumor Immunotherapy Drugs Revenue by Region: 2018-2023
3.3.2 Global Tumor Immunotherapy Drugs Revenue by Region: 2024-2029
3.4 North America Tumor Immunotherapy Drugs Market Facts & Figures by Country
3.4.1 North America Tumor Immunotherapy Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Tumor Immunotherapy Drugs Sales by Country (2018-2029)
3.4.3 North America Tumor Immunotherapy Drugs Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Tumor Immunotherapy Drugs Market Facts & Figures by Country
3.5.1 Europe Tumor Immunotherapy Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Tumor Immunotherapy Drugs Sales by Country (2018-2029)
3.5.3 Europe Tumor Immunotherapy Drugs Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Tumor Immunotherapy Drugs Market Facts & Figures by Country
3.6.1 Asia Pacific Tumor Immunotherapy Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Tumor Immunotherapy Drugs Sales by Country (2018-2029)
3.6.3 Asia Pacific Tumor Immunotherapy Drugs Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Tumor Immunotherapy Drugs Market Facts & Figures by Country
3.7.1 Latin America Tumor Immunotherapy Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Tumor Immunotherapy Drugs Sales by Country (2018-2029)
3.7.3 Latin America Tumor Immunotherapy Drugs Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Tumor Immunotherapy Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Tumor Immunotherapy Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Tumor Immunotherapy Drugs Sales by Country (2018-2029)
3.8.3 Middle East and Africa Tumor Immunotherapy Drugs Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Tumor Immunotherapy Drugs Sales by Type (2018-2029)
4.1.1 Global Tumor Immunotherapy Drugs Sales by Type (2018-2023)
4.1.2 Global Tumor Immunotherapy Drugs Sales by Type (2024-2029)
4.1.3 Global Tumor Immunotherapy Drugs Sales Market Share by Type (2018-2029)
4.2 Global Tumor Immunotherapy Drugs Revenue by Type (2018-2029)
4.2.1 Global Tumor Immunotherapy Drugs Revenue by Type (2018-2023)
4.2.2 Global Tumor Immunotherapy Drugs Revenue by Type (2024-2029)
4.2.3 Global Tumor Immunotherapy Drugs Revenue Market Share by Type (2018-2029)
4.3 Global Tumor Immunotherapy Drugs Price by Type (2018-2029)
5 Segment by Application
5.1 Global Tumor Immunotherapy Drugs Sales by Application (2018-2029)
5.1.1 Global Tumor Immunotherapy Drugs Sales by Application (2018-2023)
5.1.2 Global Tumor Immunotherapy Drugs Sales by Application (2024-2029)
5.1.3 Global Tumor Immunotherapy Drugs Sales Market Share by Application (2018-2029)
5.2 Global Tumor Immunotherapy Drugs Revenue by Application (2018-2029)
5.2.1 Global Tumor Immunotherapy Drugs Revenue by Application (2018-2023)
5.2.2 Global Tumor Immunotherapy Drugs Revenue by Application (2024-2029)
5.2.3 Global Tumor Immunotherapy Drugs Revenue Market Share by Application (2018-2029)
5.3 Global Tumor Immunotherapy Drugs Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Bristol Myer Squibb
6.1.1 Bristol Myer Squibb Corporation Information
6.1.2 Bristol Myer Squibb Description and Business Overview
6.1.3 Bristol Myer Squibb Tumor Immunotherapy Drugs Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Bristol Myer Squibb Tumor Immunotherapy Drugs Product Portfolio
6.1.5 Bristol Myer Squibb Recent Developments/Updates
6.2 AstraZeneca
6.2.1 AstraZeneca Corporation Information
6.2.2 AstraZeneca Description and Business Overview
6.2.3 AstraZeneca Tumor Immunotherapy Drugs Sales, Revenue and Gross Margin (2018-2023)
6.2.4 AstraZeneca Tumor Immunotherapy Drugs Product Portfolio
6.2.5 AstraZeneca Recent Developments/Updates
6.3 Merck
6.3.1 Merck Corporation Information
6.3.2 Merck Description and Business Overview
6.3.3 Merck Tumor Immunotherapy Drugs Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Merck Tumor Immunotherapy Drugs Product Portfolio
6.3.5 Merck Recent Developments/Updates
6.4 Roche / Genentech
6.4.1 Roche / Genentech Corporation Information
6.4.2 Roche / Genentech Description and Business Overview
6.4.3 Roche / Genentech Tumor Immunotherapy Drugs Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Roche / Genentech Tumor Immunotherapy Drugs Product Portfolio
6.4.5 Roche / Genentech Recent Developments/Updates
6.5 Ono Pharmaceutical
6.5.1 Ono Pharmaceutical Corporation Information
6.5.2 Ono Pharmaceutical Description and Business Overview
6.5.3 Ono Pharmaceutical Tumor Immunotherapy Drugs Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Ono Pharmaceutical Tumor Immunotherapy Drugs Product Portfolio
6.5.5 Ono Pharmaceutical Recent Developments/Updates
6.6 Regeneron
6.6.1 Regeneron Corporation Information
6.6.2 Regeneron Description and Business Overview
6.6.3 Regeneron Tumor Immunotherapy Drugs Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Regeneron Tumor Immunotherapy Drugs Product Portfolio
6.6.5 Regeneron Recent Developments/Updates
6.7 Innovent
6.6.1 Innovent Corporation Information
6.6.2 Innovent Description and Business Overview
6.6.3 Innovent Tumor Immunotherapy Drugs Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Innovent Tumor Immunotherapy Drugs Product Portfolio
6.7.5 Innovent Recent Developments/Updates
6.8 Hengrui Medicine
6.8.1 Hengrui Medicine Corporation Information
6.8.2 Hengrui Medicine Description and Business Overview
6.8.3 Hengrui Medicine Tumor Immunotherapy Drugs Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Hengrui Medicine Tumor Immunotherapy Drugs Product Portfolio
6.8.5 Hengrui Medicine Recent Developments/Updates
6.9 Junshi Biosciences
6.9.1 Junshi Biosciences Corporation Information
6.9.2 Junshi Biosciences Description and Business Overview
6.9.3 Junshi Biosciences Tumor Immunotherapy Drugs Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Junshi Biosciences Tumor Immunotherapy Drugs Product Portfolio
6.9.5 Junshi Biosciences Recent Developments/Updates
6.10 Pfizer, Inc
6.10.1 Pfizer, Inc Corporation Information
6.10.2 Pfizer, Inc Description and Business Overview
6.10.3 Pfizer, Inc Tumor Immunotherapy Drugs Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Pfizer, Inc Tumor Immunotherapy Drugs Product Portfolio
6.10.5 Pfizer, Inc Recent Developments/Updates
6.11 F. Hoffmann-La Roche Ltd
6.11.1 F. Hoffmann-La Roche Ltd Corporation Information
6.11.2 F. Hoffmann-La Roche Ltd Tumor Immunotherapy Drugs Description and Business Overview
6.11.3 F. Hoffmann-La Roche Ltd Tumor Immunotherapy Drugs Sales, Revenue and Gross Margin (2018-2023)
6.11.4 F. Hoffmann-La Roche Ltd Tumor Immunotherapy Drugs Product Portfolio
6.11.5 F. Hoffmann-La Roche Ltd Recent Developments/Updates
6.12 Incyte Corporation
6.12.1 Incyte Corporation Corporation Information
6.12.2 Incyte Corporation Tumor Immunotherapy Drugs Description and Business Overview
6.12.3 Incyte Corporation Tumor Immunotherapy Drugs Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Incyte Corporation Tumor Immunotherapy Drugs Product Portfolio
6.12.5 Incyte Corporation Recent Developments/Updates
6.13 NewLink Genetics Corporation
6.13.1 NewLink Genetics Corporation Corporation Information
6.13.2 NewLink Genetics Corporation Tumor Immunotherapy Drugs Description and Business Overview
6.13.3 NewLink Genetics Corporation Tumor Immunotherapy Drugs Sales, Revenue and Gross Margin (2018-2023)
6.13.4 NewLink Genetics Corporation Tumor Immunotherapy Drugs Product Portfolio
6.13.5 NewLink Genetics Corporation Recent Developments/Updates
6.14 Celldex Therapeutics, Inc
6.14.1 Celldex Therapeutics, Inc Corporation Information
6.14.2 Celldex Therapeutics, Inc Tumor Immunotherapy Drugs Description and Business Overview
6.14.3 Celldex Therapeutics, Inc Tumor Immunotherapy Drugs Sales, Revenue and Gross Margin (2018-2023)
6.14.4 Celldex Therapeutics, Inc Tumor Immunotherapy Drugs Product Portfolio
6.14.5 Celldex Therapeutics, Inc Recent Developments/Updates
6.15 GlaxoSmithKline
6.15.1 GlaxoSmithKline Corporation Information
6.15.2 GlaxoSmithKline Tumor Immunotherapy Drugs Description and Business Overview
6.15.3 GlaxoSmithKline Tumor Immunotherapy Drugs Sales, Revenue and Gross Margin (2018-2023)
6.15.4 GlaxoSmithKline Tumor Immunotherapy Drugs Product Portfolio
6.15.5 GlaxoSmithKline Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Tumor Immunotherapy Drugs Industry Chain Analysis
7.2 Tumor Immunotherapy Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Tumor Immunotherapy Drugs Production Mode & Process
7.4 Tumor Immunotherapy Drugs Sales and Marketing
7.4.1 Tumor Immunotherapy Drugs Sales Channels
7.4.2 Tumor Immunotherapy Drugs Distributors
7.5 Tumor Immunotherapy Drugs Customers
8 Tumor Immunotherapy Drugs Market Dynamics
8.1 Tumor Immunotherapy Drugs Industry Trends
8.2 Tumor Immunotherapy Drugs Market Drivers
8.3 Tumor Immunotherapy Drugs Market Challenges
8.4 Tumor Immunotherapy Drugs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock